05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Oral transmucosal drug delivery tablets for the delivery of pharmaceutical preparations. Manufacture of pharmaceutical tablets and capsules, vitamins, food supplements and animal veterinary tablets to order and/or specification of others. Research, development and consultation related thereto in the field of pharmaceutical tablets and capsules, vitamins, food supplements and animal veterinary tablets.
Disclosed herein are dosage forms demonstrating resistance against attempted liberation of hydrocodone or a salt thereof from the dosage forms by one or both of manipulation, attempted isolation of the hydrocodone or salt by chemical extraction. Also disclosed are dosage forms demonstrating resistance to pharmacokinetic changes, pharmacodynamic changes, or both, in response to attempted liberation or attempted isolation of the hydrocodone or a salt from the dosage form. Also provided are dosage forms that yield hydrocodone or a salt having a reduced degree of purity in response to manipulation of the dosage form, and extraction of the hydrocodone or salt. The present disclosure also provides dosage form demonstrating resistance against attempted liberation of hydrocodone or salt thereof from the dosage form by ingestion with alcohol. Methods of treating chronic pain by administering to a subject any of these dosage forms are also disclosed.
A61J 3/06 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
The disclosure is directed to immediate release dosage forms comprising an active agent portion comprising an active pharmaceutical agent and about 30% to about 99%, based on the weight of the dosage form, of an alcohol resistant agent. The dosage forms can include an admixture of a plurality of particles comprising an active pharmaceutical agent and the alcohol resistant agent, or can include a central core portion that comprises the active agent portion, and an outer layer comprising the alcohol resistant agent that surrounds the central core. The dosage forms prevent dose dumping of the pharmaceutical agents when administered to the patient. Also provided are methods of treating patients comprising administering to the patient an immediate release dosage form as described herein.
A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 31/515 - Barbituric acidsDerivatives thereof, e.g. sodium pentobarbital
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
A61P 25/04 - Centrally acting analgesics, e.g. opioids
Extended release, abuse deterrent dosage forms in which the active ingredient consists essentially of hydrocodone are disclosed, wherein administration of the dosage form to a subject in at least one dose per day over multiple days does not produce a therapeutically significant effect on one or more pharmacokinetic parameters following a first dose or at steady state. Methods of treating pain using such dosage forms are also provided.
Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
40 - Treatment of materials; recycling, air and water treatment,
Goods & Services
(1) Manufacture of pharmaceutical tablets and capsules, vitamins, food supplements and animal veterinary tablets to order and/or specification of others
7.
IMMEDIATE RELEASE ABUSE-DETERRENT GRANULATED DOSAGE FORMS
Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.
Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.
Described are oral dosage forms that contain abuse-deterrent features and that contain a matrix with gelling polymer and disintegrant, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.
Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
Goods & Services
Oral transmucosal drug delivery tablets for the delivery of pharmaceutical preparations. Manufacture of pharmaceutical tablets and capsules, vitamins, food supplements and animal veterinary tablets to order and/or specification of others. Research, development and consultation related thereto in the field of pharmaceutical tablets and capsules, vitamins, food supplements and animal veterinary tablets.
This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing a high water-soluble, high dose drug. The dosage form has alcohol resistance and may also have crush resistance.
This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing venlafaxine or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.
This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing metoprolol or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance.
This disclosure relates to a sustained-release oral dosage form suitable for twice-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydrocodone. The dosage form can have a release profile such that 6 hours following administration, less than about 80 percent of the hydrocodone is released. In addition, the dosage form may have alcohol and/or crush resistance.
This disclosure relates to a sustained-release oral dosage form for once-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydromorphone. The dosage form can have a release profile such that 16 hours following administration, less than about 85 percent of the hydromorphone is released. In addition, the dosage form may have alcohol and/or crush resistance.
Described here in are oral transmucosal solid dosage forms useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine, the dosage forms transmucosally delivers an effective amount of nicotine to the recipient while permitting the accomplishing of such, and manufacture of such, using a relatively small, convenient and orally comfortable dosage form (e.g., tablet) size.
This disclosure relates to dosage forms (e.g., solid dosage forms) comprising a drug-containing emulsion, a drug-containing micro-emulsion, a self-emulsifying oil composition, or a self-microemulsifying oil composition, wherein each comprises a weakly ionizable drug and a pH modifier. Also provided are pharmaceutical dosage forms (e.g., solid dosage forms) and methods of preparing same.
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A pharmaceutical composition may include a coated particulate which may include at least one active pharmaceutical ingredient, particularly one susceptible to abuse by an individual. The coated particles may include a fat/wax and have improved controlled release and/or crush resistance. Method of making these coated particulate and dosage forms therewith are also described.
The invention described herein relates to an oral transmucosal solid dosage form useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine, the invention transmucosally delivers an effective amount of nicotine to the recipient while permitting the accomplishing of such, and manufacture of such, using a relatively small, convenient and orally comfortable dosage form (e.g., tablet) size.
A pharmaceutical composition may include a granulate which may include at least one active pharmaceutical ingredient susceptible to abuse by an individual mixed with at least two materials, a first material that is substantially water insoluble and at least partially alcohol soluble and a second material that is substantially alcohol insoluble and at least partially water soluble, wherein the active pharmaceutical ingredient and the two materials are granulated in the presence of water and alcohol. The composition may also include a coating on the granulate exhibiting crush resistance which may have a material that is deposited on the granulate using an alcohol based solvent. The composition further comprises a second particle comprising a fat/wax. The present invention also includes a coated granulate, various dosage forms of the composition, as well as methods of production and tableting.
This invention relates to orally disintegrable, lorazepam-containing dosage forms which are storage stable and disintegrable within about 90 seconds or less. In one embodiment, there is provided a storage stable, orally disintegrable dosage form comprising: protected lorazepam particles comprising lorazepam and polymeric material having a glass transition temperature of about 65°C or above. Also disclosed is a method of producing a storage stable lorazepam containing tablet.
The present invention provides an orally dissolvable/disintegrable, lyophilized dosage form including a protected granulate comprising an active ingredient and a protective granulation binder, which substantially protects the form and/or attributes of a granulate and/or active ingredient, and participates in masking bad tasting active ingredients, such as sulfur-containing materials, and a matrix, and a method for making same. There is also provided a method of treating a patient using any orally dissolvable/disintegrable lyophilized dosage form comprising the steps of placing the dosage form in the mouth of a patient in need of treatment, allowing the dosage form to disintegrate/dissolve sufficiently to allow it, and in particular, the protected granulate, to be swallowed as a solution, suspension or slurry, and swallowing the at least partially disintegrated/dissolved dosage form.
The present invention provides an orally dissolvable/ disintegrable, lyophilized, dosage form adapted for direct oral dosing, including an active pharmaceutical ingredient ('API') containing particle which is coated with a lyophilizing solvent protective coating, which protects the form and/or attributes of the particle and/or API, and a matrix. There is also provided a method of making an orally dissolvable/disintegrable lyophilized dosage form in accordance with the present invention, and a method of treating a patient with a dosage form in accordance with the present invention.
The present invention relates to tablets containing prednisolone salts and in particular prednisolone sodium phosphates. The dosage forms include ODTs and non- ODTs, effervescent tablets and noneffervescent tablets and tablets meeting certain performance criteria.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
The present invention relates to tablets containing prednisolone salts and in particular prednisolone sodium phosphates. The tablets include ODTs and non- ODTs, effervescent tablets and noneffervescent tablets and tablets meeting certain performance criteria.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
The present invention relates to orally dissolvable/disintegrable dosage forms adapted for direct oral dosing comprising at least one coated active ingredient formed by co-spray drying an active ingredient and a coating. These dosage forms are harder than known orally dissolvable disintegrable dosage forms and have advantages in terms of manufacturing and storage costs.
The present invention relates to a method of producing a dried wet granulate having a desirable average particle size and particle size distribution and dosage forms made from that granulate.
The present invention relates to a method of producing a dried wet granulate having a desirable average particle size and particle size distribution and dosage forms made from that granulate.
16 - Paper, cardboard and goods made from these materials
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
[ printed informational, promotional, and educational materials, namely, pamphlets, sheets, brochures, leaflets, and posters in the fields of medical diseases and disorders and the treatment and management of thereof through the use of pharmaceuticals; promotional items, namely, pens, pencils, note pads, sticky note pads, pen holders, and pencil holders ] [ educational services, namely, conducting programs, conferences, workshops, and seminars in the fields of medical diseases and disorders and the treatment and management of thereof through the use of pharmaceuticals ] providing medical and pharmaceutical information; providing medical and pharmaceutical information via the Internet
A blister package and method of removing a dosage form from a blister package are disclosed. In one embodiment, the blister package includes a unitary blister sheet and a unitary sheet of lidding material. The lidding sheet is peelably sealed to the blister sheet, and includes unsealed areas for facilitating the peeling of the lidding material from the blister sheet. The unsealed areas are preferably only accessible upon a bending of the blister package.
B65D 85/42 - Containers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure for ampoulesContainers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure for lamp bulbsContainers, packaging elements or packages, specially adapted for particular articles or materials for articles particularly sensitive to damage by shock or pressure for electronic valves or tubes
A blister package (10) and method of removing a dosage form (1) from a blister package (10) are disclosed. In one embodiment, the blister package (10) includes a unitary blister sheet (12) and a unitary sheet of lidding material (14). The lidding sheet (14) is peelably sealed to the blister sheet (12), and includes unsealed areas (28) for facilitating the peeling of the lidding material (14) from the blister sheet (12). The unsealed areas (28) are preferably only accessible upon a bending of the blister package (10).
B65D 83/04 - Containers or packages with special means for dispensing contents for dispensing annular, disc-shaped, spherical or like small articles, e.g. tablets or pills
Fentanyl containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than know oral formulation and have advantages in terms of cost and side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa.
Opiate containing dosage forms and methods using same are described. These dosage forms include substantially less opiates by weight than known oral formulations. These dosage forms are intended for oral administration across the oral mucosa.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemical substances for carrying pharmaceutical preparations and substances, vitamins and dietary supplements; preservatives. Pharmaceutical preparations and substances; vitamins and dietary supplements; carriers for all the aforesaid. Health and medical care services.
